US Government Bans Use of Aborted Fetal Tissue in NIH-Funded Research
The Trump administration has announced a policy change that effectively bans the use of human fetal tissue derived from abortions in research funded by the National Institutes of Health (NIH), a move long advocated for by anti-abortion groups. The new restriction, which takes effect immediately, expands on previous rules implemented during President Donald Trump's first term.
In reality, the NIH has been funding research involving fetal tissue for decades, despite its contentious nature. However, opponents of such use argue that alternatives are now readily available to overcome this hurdle. Researchers claim that adequate substitutes often do not exist in certain cases, rendering it a critical component for groundbreaking studies on HIV and cancer.
According to Jay Bhattacharya, director of the NIH, "the agency has long maintained policies governing the responsible and limited use of human fetal tissue in biomedical research." The shift marks a significant decline from 2019, when only 77 projects funded by the $47 billion agency included fetal tissue. This recent change is part of a broader trend that started during Trump's first term.
It's worth noting that while the policy applies to all NIH-funded research, it does not completely halt the use of "cell lines" created from fetal cells years ago. These cloned copies of cells can be grown continuously in labs and will likely continue to be used in some form. The NIH has announced plans to seek comment on potential ways to reduce or potentially replace reliance on human embryonic stem cells.
The Trump administration has announced a policy change that effectively bans the use of human fetal tissue derived from abortions in research funded by the National Institutes of Health (NIH), a move long advocated for by anti-abortion groups. The new restriction, which takes effect immediately, expands on previous rules implemented during President Donald Trump's first term.
In reality, the NIH has been funding research involving fetal tissue for decades, despite its contentious nature. However, opponents of such use argue that alternatives are now readily available to overcome this hurdle. Researchers claim that adequate substitutes often do not exist in certain cases, rendering it a critical component for groundbreaking studies on HIV and cancer.
According to Jay Bhattacharya, director of the NIH, "the agency has long maintained policies governing the responsible and limited use of human fetal tissue in biomedical research." The shift marks a significant decline from 2019, when only 77 projects funded by the $47 billion agency included fetal tissue. This recent change is part of a broader trend that started during Trump's first term.
It's worth noting that while the policy applies to all NIH-funded research, it does not completely halt the use of "cell lines" created from fetal cells years ago. These cloned copies of cells can be grown continuously in labs and will likely continue to be used in some form. The NIH has announced plans to seek comment on potential ways to reduce or potentially replace reliance on human embryonic stem cells.